EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Clinical prognostic impact of long noncoding RNA in cholangiocarcinoma: a systematic review and meta-analysis

Zaiba Shafik Dawood, Abdul Ali, Meher Angez, Timothy M. Pawlik

Frontiers in Oncology · 18.11.2026 · 16

DOI: 10.3389/fonc.2026.1977595 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Frontiers in Oncology, online erschienen am 18.11.2026. Verfasst von Zaiba Shafik Dawood und 3 weiteren Autor:innen. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Cholangiocarcinoma (CCA) is a rare, aggressive malignancy with poor prognosis. Long non-coding RNA (LncRNA) are noncoding transcripts that play a role in transcriptional, post-transcriptional and epigenetic regulation. Dysregulated LncRNA expression has been associated with adverse oncologic outcomes and may serve as a prognostic biomarker in CCA. This systematic review and meta-analysis evaluated the prognostic impact of LncRNA expression among patients with CCA.

Methods

A systematic search of PubMed, Embase, and Scopus was performed using Boolean search terms and Medical Subject Headings for bile duct neoplasms, cholangiocarcinoma, and long non-coding RNA. Random-effects meta-analysis was used to evaluate the association of LncRNA expression with overall survival (OS) and disease-free survival (DFS).

Results

Thirty-two studies including 1622 patients met inclusion criteria; 53.2% of patients were male. Increased LncRNA expression was associated with worse OS (HR, 1.70; 95% CI, 1.53–1.91; P<.001) and DFS (HR, 2.42; 95% CI, 1.30–4.50; P<.001). The pooled area under the curve for LncRNA-based prognostic models was 0.86 (95% CI, 0.77–0.95; I²=85.6%; P<.000, suggesting good prognostic discrimination. Funnel plots and Egger’s tests demonstrated evidence of publication bias for OS (P = .03) and DFS (P = .013). In sensitivity analyses excluding smaller studies, the pooled effect estimates remained similar.

Conclusion

LncRNA may serve as promising as prognostic biomarkers in patients with cholangiocarcinoma. Large-scale prospective studies are needed to validate its clinical relevance before routine clinical implementation. Systematic review registration https://www.crd.york.ac.uk/PROSPERO/view/CRD420251103592 , identifier CRD420251103592.

Zitieren

APA

Dawood, Z. S., Ali, A., Angez, M., & Pawlik, T. M. (2026). Clinical prognostic impact of long noncoding RNA in cholangiocarcinoma: a systematic review and meta-analysis. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1977595

Vancouver

Dawood ZS, Ali A, Angez M, Pawlik TM. Clinical prognostic impact of long noncoding RNA in cholangiocarcinoma: a systematic review and meta-analysis. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1977595

BibTeX
@article{Dawood2026,
  author = {Dawood, Zaiba Shafik and Ali, Abdul and Angez, Meher and Pawlik, Timothy M.},
  title = {Clinical prognostic impact of long noncoding RNA in cholangiocarcinoma: a systematic review and meta-analysis},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1977595}
}
Kostenlos starten →